在老年人心血管风险预测
Lisandro D Colantonio1, Vera Bittner2
1Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Current atherosclerosis reports
|September 9, 2025
概括
对老年人的心血管疾病 (CVD) 风险模型显示可接受的歧视但可变的校准. 纳入老年因素可能会提高心血管疾病风险预测在这个不断增长的人口的准确性.
科学领域:
- 老年学是一门学科.
- 心脏病学 心脏病学
- 流行病学 流行病学
背景情况:
- 老年人代表着快速增长的人口,心血管疾病 (CVD) 风险显著增加.
- 准确的心血管疾病风险预测对于指导预防策略和共同决策至关重要.
- 挑战包括与年龄相关的风险异质性,竞争的非心血管疾病死亡风险和并发症.
研究的目的:
- 审查现有的适用于老年人心血管疾病 (CVD) 风险预测模型.
- 讨论这些模型的特征,性能指标和临床影响.
- 确定改善老年人心血管疾病风险评估的潜在领域.
主要方法:
- 对有关心血管疾病风险预测模型的已发表文献进行系统审查.
- 对模型特征的分析,包括预测因素,结果和统计方法.
- 评估模型性能指标,如歧视和校准.
主要成果:
- 对于老年人来说,有几种心血管疾病风险模型存在,具有不同的预测因素,结果和统计方法.
- 模式歧视通常是可以接受的,但与年轻人相比,在老年人中通常是温和的.
- 在不同的人群中,校准性能差异很大,这突显了对特定环境验证的需求.
结论:
- 目前的心血管疾病风险模型为预测老年人心血管事件提供了基础.
- 改善歧视可能需要将老年特异性因素纳入现有模型.
- 需要进一步的研究来完善和验证根据老龄化人口的独特需求量身定制的CVD风险预测工具.
相关概念视频
Assessment of the Cardiovascular System I: Subjective Data
730
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
730
Coronary Artery Disease IV: Preventive Measures
563
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
563
Coronary Artery Disease I: Introduction
843
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290


